Results 141 to 150 of about 2,201,777 (199)

Investigating the mechanism of Fuzheng Sanjie Formula in regulating osimertinib resistance in NSCLC via the CAFs-TIMP3-MMP9 axis: a study integrating network pharmacology, data mining. [PDF]

Front Oncol
Wang Y, Peng Q, Zhang Y, Wang H, Zhu J, Zhou J.   +5 more
europepmc   +1 more source

TRIM26-mediated NKRF degradation drives Osimertinib resistance through SNRPD2-dependent stress granule formation in lung adenocarcinoma. [PDF]

Cell Death Dis
Wang T, Yang HY, Wang X, Han XH, Zhang Z, Zhang Y, Han XJ, Lu Z.   +7 more
europepmc   +1 more source

TRMT1-mediated tRNA m²₂G modification drives Osimertinib resistance via the ATXN3/USP25 axis in lung adenocarcinoma. [PDF]

Cell Death Dis
Li J, Jing B, Wang Y, Bai W, Wei Q, Zhu C, Ling X, Liu M, Huang K, Pan S, Dong H, Lu H, Qian J, Ji Y, Liu W, Zhong H, Zhang Y, Wu W, Zhai Y, Luo H, Lei H, Xu H, Wu Y, Chu T.   +23 more
europepmc   +1 more source

Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance. [PDF]

J Extracell Vesicles
Cáceres-Verschae A, Hååg P, Joelsson S, Hydbring P, Franzén B, Végvári Á, Eide IJZ, Agarwal N, Sahu SS, Stridfeldt F, De Petris L, Dev A, Ekman S, Brustugun OT, Lewensohn R, Viktorsson K.   +15 more
europepmc   +1 more source

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. [PDF]

Cell Oncol (Dordr)
Wang Y, Guo H, Han R, Wu Y, He T, Diao M, Xiong A, Zhou F, Cheng L, Zhao C, Li X, Zhou C.   +11 more
europepmc   +1 more source

Acquired <i>EML4-ALK</i> fusion and <i>BRAF</i> V600G dual bypass activation following osimertinib resistance in lung adenocarcinoma and successful treatment with lorlatinib: a case report. [PDF]

Front Oncol
Zhang R, Li J.
europepmc   +1 more source

USP5-mediated CD73 deubiquitination drives osimertinib resistance via PI3K/AKT and glycolysis activation in LUAD. [PDF]

iScience
Chen R, Han XH, Zhang Z, Han XJ, Xie J.
europepmc   +1 more source

Exosomes-Transferred lncRNA H19 Reverses Osimertinib Resistance by Upregulating PTEN via Sponging miR-148-3p in Non-Small Cell Lung Cancer. [PDF]

Oncol Res
Song W, Zhang Y, Shen X, Yu Q, Liu Y, Yu Y, Chen R.   +6 more
europepmc   +1 more source

Loss of tumor suppressor circRNA CircSPINT2 drives osimertinib resistance in lung adenocarcinoma. [PDF]

Mol Ther Oncol
Bhatia R, Chaudhary S.
europepmc   +1 more source

Correction: Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer. [PDF]

Cell Death Dis
Dayanc B, Eris S, Gulfirat NE, Ozden-Yilmaz G, Cakiroglu E, Coskun Deniz OS, Karakülah G, Erkek-Ozhan S, Senturk S.   +8 more
europepmc   +1 more source